EQS-News: Biotest AG
/ Key word(s): Regulatory Approval
PRESS RELEASE
Milestone for Biotest: US approval for innovative immunoglobulin Yimmugo
Dreieich, Germany, June 17, 2024. Biotest AG today announced that its intravenous immunoglobulin Yimmugo® has been approved in the United States for the treatment of patients with primary immunodeficiencies (PID). At the same time, the site in Dreieich, Germany, has been certified by the FDA. Previously, Biotest had already received approval for production and marketing in European markets. "With this approval, we aim to increase the availability of and access to immunoglobulin therapies worldwide, thereby improving patient care," said Peter Janssen, CEO of Biotest AG. "We are very pleased that with Yimmugo® we can bring a product from Germany to the American market for the first time in the history of Biotest.” Yimmugo® is the first drug approved in the U.S. to be manufactured using an innovative process in the new "Biotest Next Level" production facility. It was analyzed for safety, efficacy and tolerability in extensive pivotal studies. The U.S. approval was preceded by an approval process with the U.S. Food and Drug Administration (FDA) in which Yimmugo® and its manufacturing facility were successfully demonstrated to meet the FDA's approval requirements within the first cycle and without delay. This is a great achievement for Biotest's employees and partners, who have worked with great dedication on the development of the product and the realization of the modern production facility with state-of-the-art technology.
About Yimmugo® (IgG Next Generation) Yimmugo® is a newly developed polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIg). The sugar-free ready-to-use solution is approved in Europe for substitution therapy in primary antibody deficiency syndromes and secondary immune deficiency, as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki syndrome. Under the US License Biotest is authorized to manufacture Yimmugo® for the treatment of primary humoral deficiency (PI) in patients 2 years of age or older. Yimmugo® is the first approved product from the new Biotest Next Level production facility. The modern production process stands for highest product quality and an extremely responsible use of resources.
About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).
Biotest AG will now also be publishing official press releases via X. You can find us at: https://twitter.com/BiotestAG
IR contact Dr Monika Baumann (Buttkereit) Phone: +49-6103-801-4406
PR contact Dirk Neumüller Phone: +49-6103-801-269
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Preference shares: securities’ ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Disclaimer
17.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 - 8 01-0 |
Fax: | 0 61 03 - 8 01-150 |
E-mail: | ir@biotest.com |
Internet: | www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1925909 |
End of News | EQS News Service |
|
1925909 17.06.2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.